For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The LANCE® Ultra Human CCL4/MIP-1ß Detection Kit is designed for detection and quantitation of human CCL4/MIP-1ß in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
C-C Motif Chemokine 4 (CCL4), also known as Macrophage Inflammatory Protein-1beta (MIP-1ß), is a 69 amino acid chemokine signaling through the CCR5 receptor. It is a chemoattractant for natural killer cells, monocytes, and a variety of other immune cells. CCL4 is also an important regulator of macrophage migration. CCL4 is rapidly synthesized by activated T cells, B cells, and monocytes. It is also produced by neutrophils after adhesion to the laminin contained in the basement membrane of blood vessels. It is one of the major HIV-suppressive factors produced by CD8+ T-cells and has been reported to show a direct antiviral activity against HSV-1. Recombinant CCL4 also induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus.
|Assay Target Class||Cytokine|
|Detection Method||Time-Resolved Fluorescence (TRF), TR-FRET|
|Experimental Type||In vitro|
|Shipping Condition||Blue Ice|
|Unit Size||500 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.